Pulmonary hypertension (PH) is an important complication of chronic parenchymal lung diseases. The current definition of PH requires an abnormal resting mean pulmonary arterial pressure >20 mmHg during right heart catheterization (RHC). The most common chronic lung conditions that cause PH are chronic...
Alright, as a quick recap, in pulmonary hypertension the mean pulmonary arterial pressure is greater than 25 mm Hg. It can be due to left heart disease, chronic lung disease, or conditions that specifically cause pulmonary arterial hypertension. Regardless of the cause, it can lead to right-si...
Five main groups of pulmonary hypertension are recognized, all defined by a mean pulmonary artery pressure of >20 mmHg: pulmonary arterial hypertension (rare), pulmonary hypertension associated with left-sided heart disease (very common), pulmonary hypertension associated with lung disease (common),...
Pulmonary hypertension due to heart disease involves increased pressure in the blood vessels of the lung from heart failure or problems with the heart valves. Pulmonary hypertension due to lung disease is caused by low oxygen levels from lung illnesses (su...
pulmonary hypertension, which currently relies on right heart catheterisation. Given the global burden of chronic lung disease, screening strategies and non-invasive diagnostic tools need to be established, especially for low-income countries where the prevalence of chronic lung disease is high and ...
Pulmonary arterial hypertension (PAH) associated with chronic lung disease of infancy can be a life-threatening disease affecting an increasing number of former premature infants. There is a need for improved delivery of targeted PAH therapies for this subgroup of patients who have severe and persiste...
Administration of small doses of MCT or its active metabolite, monocrotaline pyrrole (MCTP), to rats causes delayed and progressive lung injury characterized by pulmonary vascular remodeling, pulmonary hypertension, and compensatory right heart hypertrophy. The lesions induced by MCT(P) administration in...
12. Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med 2018;6:577-579. 13. Wu W, He J, Shao X. Incidence and mortality trend of congenital heart disease at the global, regional, and national level, 1990–2017. Me...
肺动脉高压、慢性血栓栓塞、无深静脉血栓(Pulmonary Hypertension, Chronic Thromboembolic, Without Deep Vein Thrombosis)遗传基础和突变分析 肺动脉高压、慢性血栓栓塞、无深静脉血栓是一种罕见的遗传性疾病,其遗传基础和突变分析仍在研究中。目前已知的一些可能与该疾病相关的基因包括BMPR2、ACVRL1、ENG、SMAD9等。这些...
In addition, an entity of ‘unexplained pulmonary hypertension,’ group 5, in patients with chronic kidney disease and end-stage renal disease has emerged, with prevalence estimates of 30–50%. The pathogenesis of pulmonary hypertension in this population is due to alterations in endothelial ...